ASCO: GenFleet’s KRAS G12C/EGFR Combo Sets Sail In First-Line NSCLC

IO, Chemo-Free Strategy

Excluding PD-1 inhibitors in its combination strategy for oncology, preliminary results from GenFleet’s Phase II KROCUS study presented at ASCO demonstrate promising efficacy for fulzerasib plus cetuximab in the first-line treatment of KRAS G12C-mutated, advanced non-small cell lung cancer.

set sail
GenFleet sets sail in first-line KRAS G12C-mutated NSCLC with novel combo strategy excluding PD-1s • Source: Shutterstock

Amid the global race to scour for the best partners and approaches for KRAS G12C inhibitors for the first-line treatment of advanced non-small cell lung cancer (NSCLC) harboring the hard-to-drug mutation, Chinese biotech GenFleet Therapeutics has conjured up an immunotherapy- or chemotherapy-free strategy.

More from China

AstraZeneca Expands Emphasis On China, Already A Key Market

 
• By 

UK pharma will invest $2.5bn in Beijing R&D hub, build a vaccine manufacturing site with BioKangtai, and partner in chronic disease with Syneron and in oncology/immunology with Harbour BioMed.

Kelun Wins World’s First TROP2 ADC Approval In Lung Cancer

 

While diverging from partner Merck & Co. in its study dosage of sacituzumab tirumotecan, Kelun has garnered the world’s first approval, in China, for a TROP2-targeting antibody-drug conjugate, for the treatment of lung cancer.

TYK’s EGFR Inhibitor Bests Tagrisso In NSCLC Brain Metastases

 

Chinese biotech TYK Medicines says its EGFR inhibitor outperformed AstraZeneca’s same-class blockbuster Tagrisso in a pivotal Phase II trial for first-line use in brain metastases resulting from EGFR mutation-positive non-small cell lung cancer.

Chinese First-In-Class Endeavors See Triumphs, Setbacks In Early 2025

 

Following approvals in China, Trinomab and Keymed have become world-first movers in tetanus prophylaxis and seasonal allergic rhinitis, respectively. But Lepu and RDO Pharm have seen their hopes for approval of an EGFR-targeting antibody-drug conjugate and an imaging agent fizzle.

More from Focus On Asia

Profile: Anil Koul’s Journey From ‘Jumping Genes’ To Sirturo And AI-Led Drug Discovery

 

Professor Anil Koul shares vignettes of his life and career trajectory, a captivating mix of hope, science and destiny that took him to the lab of eminent cancer biologist Alex Ullrich at the Max Planck Institute and also saw him contribute to the development of breakthrough TB drug bedaquiline. He also talks about Medicine 3.0 and the intersection of science and spirituality.

AstraZeneca Expands Emphasis On China, Already A Key Market

 
• By 

UK pharma will invest $2.5bn in Beijing R&D hub, build a vaccine manufacturing site with BioKangtai, and partner in chronic disease with Syneron and in oncology/immunology with Harbour BioMed.

Korea Needs To Think Bigger On M&As: KHIDI

 

A new report from a domestic institute on South Korea’s biopharma M&A trends shows a pickup in activity, but that this remains relatively weak and small-scale. It calls for broader domestic government support to build expertise, drive innovation and globalization.